GlassScriptPhysician profile
Wes S Lee
NPI 1376633149
$6,196.23
in general payments reported to CMS, 2019-2025
49 companies · $883 in 2025
The $883 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $640 · 2021: $1,531 · 2022: $1,236 · 2023: $282 · 2024: $446 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.98 |
| Education | $112.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $687.79 | 2019-2025 | Enhertu, Tagrisso, Lynparza |
| Glaxosmithkline, LLC. | $535.63 | 2020-2025 | Ojjaara |
| Merck Sharp & Dohme LLC | $392.06 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $352.84 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $348.24 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $326.10 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $285.00 | 2019-2025 | Darzalex, Akeega, Erleada |
| Lilly USA, LLC | $262.73 | 2019-2025 | Jaypirca, Verzenio |
| Pharmacyclics LLC, An Abbvie Company | $238.94 | 2020-2022 | |
| Daiichi Sankyo INC. | $235.33 | 2021-2025 | Enhertu |
| Genentech USA, INC. | $225.19 | 2019-2025 | Tecentriq Hybreza |
| Genzyme Corporation | $197.55 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.62 | 2019-2025 | Fruzaqla, Iclusig, Ninlaro |
| Eisai INC. | $151.42 | 2020-2022 | |
| Progenics Pharmaceuticals, INC. | $150.24 | 2023 | Pylarify |
Show all 46 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wes Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.